Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial

Trial Profile

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Calcium; Vitamin D
  • Indications Advanced breast cancer; Bone disorders; Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms REDUSE
  • Most Recent Events

    • 16 Feb 2019 Results (n=383) of interim analysis for the secondary endpoint hypocalcemia presented at the 2019 Genitourinary Cancers Symposium
    • 17 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 06 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top